Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/25493
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mederacke, Ingmar | - |
dc.contributor.author | Yurdaydın, Cihan | - |
dc.contributor.author | Grosshennig, Anika | - |
dc.contributor.author | Erhardt, Andreas | - |
dc.contributor.author | Çakaloğlu, Yılmaz | - |
dc.contributor.author | Yalçın, Kendal | - |
dc.contributor.author | Zeuzem, Stefan | - |
dc.contributor.author | Zachou, Kalliopi | - |
dc.contributor.author | Chatzikyrkou, Christos | - |
dc.contributor.author | Bozkaya, Hakan | - |
dc.contributor.author | Dalekos, George Nikolaos | - |
dc.contributor.author | Manns, Michael Peter | - |
dc.contributor.author | Wedemeyer, Heiner | - |
dc.date.accessioned | 2022-03-31T11:00:04Z | - |
dc.date.available | 2022-03-31T11:00:04Z | - |
dc.date.issued | 2012-06 | - |
dc.identifier.citation | Mederacke, I. vd. (2012). "Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection". Journal of Viral Hepatitis, 19(6), 387-395. | en_US |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.issn | 1365-2893 | - |
dc.identifier.uri | https://doi.org/10.1111/j.1365-2893.2011.01560.x | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01560.x | - |
dc.identifier.uri | http://hdl.handle.net/11452/25493 | - |
dc.description.abstract | Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNa). The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNa-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. We performed a retrospective analysis of renal function data of patients treated in the Hep-Net/International Delta Hepatitis Intervention Trial 1(HIDIT-1-trial), a European multicenter study to investigate the efficacy of 48 weeks of therapy with PegIFNa-2a+ADV vs either drug alone in 90 patients with chronic hepatitis B/D co-infection. Glomerular filtration rates (GFR) were calculated by CockcroftGault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. After 48 weeks of therapy GFR values were significantly lower in patients receiving adefovir-containing treatment vs PegIFNa-2a alone [mean difference 16.1 mL/min (CG) and 10.2 mL/min (MDRD), respectively, P < 0.05] while no differences were observed between patients receiving adefovir alone vs combination treatment. Twenty-four weeks after treatment GFR values did not differ between treatment arms. A decrease in GFR =20% was observed more often in patients during adefovir-containing treatment vs PegIFNa-2a alone (P < 0.05) which was confirmed by KaplanMeier analysis. Adefovir-containing but not PegIFNa-2a treatment was associated with a decrease in GFR values in about one-fifth of patients. Combination treatment of PegIFNa-2a+ADV in chronic hepatitis B/D co-infection did not lead to any further impairment of kidney function. | en_US |
dc.description.sponsorship | Hep-Net Study House | en_US |
dc.description.sponsorship | Federal Ministry of Education & Research (BMBF) | en_US |
dc.description.sponsorship | Hoffmann-La Roche | en_US |
dc.description.sponsorship | Gilead Sciences | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Gastroenterology & hepatology | en_US |
dc.subject | Infectious diseases | en_US |
dc.subject | Virology | en_US |
dc.subject | Adefovir | en_US |
dc.subject | Combination therapy | en_US |
dc.subject | Glomerular filtration rate | en_US |
dc.subject | Interferon | en_US |
dc.subject | Renal function | en_US |
dc.subject | Safety | en_US |
dc.subject | Glomerular-filtration-rate | en_US |
dc.subject | Delta-virus-infection | en_US |
dc.subject | Serum creatinine | en_US |
dc.subject | Combination | en_US |
dc.subject | Lamivudine | en_US |
dc.subject | Prediction | en_US |
dc.subject | Management | en_US |
dc.subject | Cirrhosis | en_US |
dc.subject | Equation | en_US |
dc.subject | Therapy | en_US |
dc.subject.mesh | Adenine | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aleutian mink disease virus | en_US |
dc.subject.mesh | Antiviral agents | en_US |
dc.subject.mesh | Drug therapy, combination | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Hepatitis b | en_US |
dc.subject.mesh | Hepatitis d | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Interferon-alpha | en_US |
dc.subject.mesh | Kidney | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Phosphonic acids | en_US |
dc.subject.mesh | Polyethylene glycols | en_US |
dc.subject.mesh | Recombinant proteins | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Young adult | en_US |
dc.title | Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000303858900002 | tr_TR |
dc.identifier.scopus | 2-s2.0-84861101465 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi. | tr_TR |
dc.identifier.startpage | 387 | tr_TR |
dc.identifier.endpage | 395 | tr_TR |
dc.identifier.volume | 19 | tr_TR |
dc.identifier.issue | 6 | tr_TR |
dc.relation.journal | Journal of Viral Hepatitis | en_US |
dc.contributor.buuauthor | Gürel, Selim | - |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.identifier.pubmed | 22571900 | tr_TR |
dc.subject.wos | Gastroenterology & hepatology | en_US |
dc.subject.wos | Infectious diseases | en_US |
dc.subject.wos | Virology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q2 | en_US |
dc.contributor.scopusid | 7003706434 | tr_TR |
dc.subject.scopus | Hepatitis B E Antigen; Entecavir; Telbivudine | en_US |
dc.subject.emtree | Adefovir | en_US |
dc.subject.emtree | Peginterferon alpha2a | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Delta agent hepatitis | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Glomerulus filtration rate | en_US |
dc.subject.emtree | Hepatitis b | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Kidney function | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Mixed infection | en_US |
dc.subject.emtree | Monotherapy | en_US |
dc.subject.emtree | Multicenter study | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Randomized controlled trial | en_US |
dc.subject.emtree | Retrospective study | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.